Neurocrine Biosciences stock fell 1.4 percent before research event

Published on 10/07/2026 at 06:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neurocrine Biosciences stock traded at USD 142.23 on October 6, 2026, while Q2 revenue reached USD 959 million, up 39.5 percent year over year. Guggenheim set USD 207.

NBIX, US64125C1099, Illustration mit AI erstellt.

Neurocrine Biosciences stock fell 1.4 percent to USD 142.23 on Nasdaq on October 6, 2026, as the company prepared to present new Prader-Willi syndrome research. The event adds a pipeline checkpoint to a stock whose latest quarterly revenue reached USD 959 million.

Research event starts October 7

According to StockTitan, Neurocrine announced on September 30, 2026, that it would present research at the Foundation for Prader-Willi Research annual symposium beginning October 7, 2026. The program covers VYKAT XR, an approved treatment for hyperphagia, with studies focused on real-world use, caregiver experience and treatment safety.

The company scheduled multiple poster presentations for October 7, 2026, including baseline data from the PWS-VISTA observational study and findings on adverse events. A separate presentation is scheduled for October 8, 2026, giving the event a direct connection to Neurocrine's commercial and clinical pipeline.

Quarterly growth sets the benchmark

Neurocrine reported USD 959 million in second-quarter 2026 revenue, according to MarketBeat. Revenue rose 39.5 percent from the comparable quarter, while reported EPS of USD 2.85 exceeded the USD 1.65 consensus estimate by USD 1.20. The latest quarter therefore gives investors a measurable benchmark for judging whether pipeline developments can extend the company's growth profile.

The finance statements show second-quarter 2026 net income attributable to common shareholders of USD 144.4 million and cash from operating activities of USD 136.4 million. Neurocrine also held USD 332.4 million in cash and cash equivalents at June 30, 2026.

Analyst targets stay above the stock

Guggenheim initiated coverage with a Buy rating and a USD 207 price target on October 6, 2026, MarketBeat reported. The target lies 45.5 percent above the prior close cited in that report, while the stock was trading at USD 142.23 during the October 6 session.

MarketBeat's October 2, 2026 consensus covered 24 analysts and showed a Moderate Buy rating, including 18 Buy ratings, five Holds and one Strong Buy. The average 12-month target was USD 202.73, which lies 42.6 percent above USD 142.23. That gap makes the upcoming research disclosures relevant to the valuation debate, but it does not replace clinical or commercial execution.

NBIX remains below its yearly high

Neurocrine Biosciences stock was trading at USD 142.23 on Nasdaq on October 6, 2026, with the session move at minus 1.4 percent. The 52-week range was USD 122.14 to USD 186.12, and market capitalization stood at USD 14.5 billion on the same date.